NASDAQ:ADAG Adagene (ADAG) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free ADAG Stock Alerts $2.75 +0.10 (+3.77%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$2.75▼$2.7550-Day Range$2.50▼$3.5052-Week Range$1.10▼$4.38Volume744 shsAverage Volume89,652 shsMarket Capitalization$121.33 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Adagene alerts: Email Address Adagene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside81.8% Upside$5.00 Price TargetShort InterestHealthy0.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.90) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.44 out of 5 starsMedical Sector460th out of 907 stocksPharmaceutical Preparations Industry209th out of 418 stocks 3.5 Analyst's Opinion Consensus RatingAdagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdagene has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.04% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adagene has recently decreased by 38.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdagene does not currently pay a dividend.Dividend GrowthAdagene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAG. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adagene insiders have not sold or bought any company stock.Percentage Held by Insiders21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.51% of the stock of Adagene is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adagene are expected to decrease in the coming year, from ($0.90) to ($1.42) per share.Price to Book Value per Share RatioAdagene has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsWill this $2 AI stock double overnight?It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>> About Adagene Stock (NASDAQ:ADAG)Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.Read More ADAG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADAG Stock News HeadlinesApril 10, 2024 | investing.comMorgan Stanley lifts Adagene stock target on positive dataMarch 31, 2024 | finanznachrichten.deAdagene Inc.: Adagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateApril 25, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.March 29, 2024 | globenewswire.comAdagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 7, 2024 | globenewswire.comAdagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory BoardFebruary 27, 2024 | globenewswire.comAdagene to Present at the Leerink Partners Global Biopharma Conference 2024February 9, 2024 | finance.yahoo.comAdagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)January 21, 2024 | seekingalpha.comWeek In Review: Lee's Pharm Signs $138M Agreement For China Rights To Heart Failure TherapyApril 25, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.January 19, 2024 | msn.comMesoblast rises after cell therapy gets FDA rare pediatric disease designationJanuary 18, 2024 | benzinga.comHow Is The Market Feeling About Adagene?January 17, 2024 | realmoney.thestreet.comMorgan Stanley 'encouraged' by 2 cPRs reported by AdageneJanuary 17, 2024 | benzinga.comWhy Is Cancer Focused Adagene Stock Plummeting Today?January 17, 2024 | msn.comAdagene falls after trial data for cancer therapyJanuary 16, 2024 | finance.yahoo.comAdagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)January 10, 2024 | finance.yahoo.comAdagene Inc.'s (NASDAQ:ADAG) market cap surged US$34m last week, retail investors who have a lot riding on the company were rewardedJanuary 4, 2024 | finance.yahoo.comAdagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI SymposiumDecember 28, 2023 | msn.comNKGen doses first patient in Phase 1/2a Alzheimer's studyDecember 20, 2023 | realmoney.thestreet.comAdagene price target lowered by 40c at Morgan Stanley, here's whyDecember 19, 2023 | markets.businessinsider.comDeka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of DirectorsNovember 3, 2023 | finance.yahoo.comAdagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023October 13, 2023 | finance.yahoo.comAre Medical Stocks Lagging Medpace (MEDP) This Year?October 12, 2023 | finance.yahoo.comAdagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingOctober 5, 2023 | msn.comAdagene Inc - ADR (ADAG) Price Target Increased by 9.87% to 14.04October 4, 2023 | markets.businessinsider.comAdagene’s Strong Potential: A Buy Rating Backed by Evorpacept Trials and Promising CD47-Targeted TherapiesSeptember 9, 2023 | finance.yahoo.comPotential Upside For Adagene Inc. (NASDAQ:ADAG) Not Without RiskSeptember 7, 2023 | finance.yahoo.comAdagene to Present at Investor and Scientific Conferences in SeptemberSee More Headlines Receive ADAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADAG CUSIPN/A CIK1818838 Webwww.adagene.com Phone86-512-8777-3632FaxN/AEmployees174Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+81.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.19 Current Ratio3.61 Quick Ratio3.61 Sales & Book Value Annual Sales$18.11 million Price / Sales6.70 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book1.71Miscellaneous Outstanding Shares44,120,000Free Float34,764,000Market Cap$121.33 million OptionableNot Optionable Beta0.44 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Peter P. Luo Ph.D. (Age 58)Co- Founder, Chairman, CEO and President of R&D Mr. Man Kin Tam M.B.A. (Age 47)CFO & Director Dr. Jc Xu M.D. (Age 59)Ph.D., Chief Scientific Officer Ms. Ami Celeste KnoeflerVice President of Investor Relations & Corporate CommunicationsMs. Ling ZhouHead of Human ResourcesDr. Qinghai Zhao (Age 63)Chief Manufacturing Officer Ms. Yan Li M.B.A. (Age 49)Senior VP of Bioinformatics & Information Technology and Director Ms. Xiaohong She (Age 57)Senior VP & Head of Clinical Operations Dr. Guizhong Liu Ph.D. (Age 53)Senior Vice President of Early Drug Discovery Mr. Alexander Goergen (Age 37)VP & Head of Business Development More ExecutivesKey CompetitorsNuvectis PharmaNASDAQ:NVCTCoya TherapeuticsNASDAQ:COYAPDS BiotechnologyNASDAQ:PDSBInterCureNASDAQ:INCRSocietal CDMONASDAQ:SCTLView All CompetitorsInstitutional OwnershipWuXi AppTec Co. Ltd.Bought 4,225,696 shares on 2/6/2024Ownership: 9.641%View All Institutional Transactions ADAG Stock Analysis - Frequently Asked Questions Should I buy or sell Adagene stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADAG shares. View ADAG analyst ratings or view top-rated stocks. What is Adagene's stock price target for 2024? 1 analysts have issued 1 year price objectives for Adagene's stock. Their ADAG share price targets range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 81.8% from the stock's current price. View analysts price targets for ADAG or view top-rated stocks among Wall Street analysts. How have ADAG shares performed in 2024? Adagene's stock was trading at $1.9314 at the beginning of the year. Since then, ADAG stock has increased by 42.4% and is now trading at $2.75. View the best growth stocks for 2024 here. Are investors shorting Adagene? Adagene saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 13,700 shares, a decrease of 38.6% from the March 15th total of 22,300 shares. Based on an average daily trading volume, of 105,400 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are short sold. View Adagene's Short Interest. When did Adagene IPO? Adagene (ADAG) raised $133 million in an initial public offering (IPO) on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager. How do I buy shares of Adagene? Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADAG) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.